


Supplementary Figure 28



Supplementary Figure S28. Removal of mutant TP53 does not impact the response of human colon cancer derived organoids to anti-cancer agents *in vivo*

A. Growth rates of tumor xenografts of the WCB123LU human colon cancer derived organoids, for tumors derived from control cancer cells expressing mutant TP53 or from their mutant TP53 deleted derivatives. Mice were treated on the days indicated with the indicated dose of 5-FU (N=3 mice per cell line). Data are presented as mean \pm SEM of fold-change in tumor volume from the 3 independent mice for each type of cancer cell. **B.** Histology images showing H&E staining, or staining for mutant TP53 or Ki67, a marker of cell proliferation, in the tumors (*sgNC* or *sgTP53*) described in (**A**) taken from untreated mice or mice that had been treated with 5-FU. No significant differences in tumor growth or Ki67 staining were observed between the mutant TP53 deleted tumors compared to the control tumors expressing mutant TP53. The data shown in (**B**) are representative of 3 independent mice per type of cancer cell and treatment.